Anixa Biosciences says Australia accepts patent for breast cancer vaccine technology - ANIX News | RalliesAnixa Biosciences says Australia accepts patent for breast cancer vaccine technology
A
ANIX• Australia accepts patent for breast cancer vaccine technology
- Anixa Biosciences received an IP Australia Notice of Acceptance for a patent covering its breast cancer vaccine technology.
- The patent, titled “Vaccine Adjuvants and Formulations,” is exclusively licensed from Cleveland Clinic.
- Anixa cited Phase 1 data showing the vaccine was safe and generated immune responses in more than 74% of participants.
- The Australian acceptance expands patent coverage beyond the U.S., supporting potential future commercialization outside the U.S.
DASH
•
